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The molecular chaperone heat shock protein 90 (Hsp90) affects the function of many oncogenic
signaling proteins including nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) expres-
sed in anaplastic large cell lymphoma (ALCL). While ALK-positive ALCL cells are sensitive to the
Hsp90 inhibitor and the geldanamycin (GA) analog, 17-allylamino-17-demethoxygeldanamycin
(17-AAG), the proteomic effects of these drugs on ALK-positive ALCL cells are unpublished. In
this study, we investigated the cellular, biologic, and proteomic changes occurring in ALK-posi-
tive ALCL cells in response to GA treatment. GA induced G2/M cell cycle arrest and caspase-3-
mediated apoptosis. Furthermore, quantitative proteomic changes analyzed by cleavable isotope-
coded affinity tag™-LC-MS/MS (cICAT™-LC-MS/MS) identified 176 differentially expressed pro-
teins. Out of these, 49 were upregulated 1.5-fold or greater and 70 were downregulated 1.5-fold or
greater in GA-treated cells. Analysis of biological functions of differentially expressed proteins
revealed diverse changes, including induction of proteins involved in the 26S proteasome as well
as downregulation of proteins involved in signal transduction and protein and nucleic acid me-
tabolism. Pathway analysis revealed changes in MAPK, WNT, NF-kB, TGFb, PPAR, and integrin
signaling components. Our studies reveal some of the molecular and proteomic consequences of
Hsp90 inhibition in ALK-positive ALCL cells and provide novel insights into the mechanisms of
its diverse cellular effects.
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1 Introduction
Anaplastic large cell lymphoma (ALCL) is a type of non-
Hodgkin lymphoma that commonly harbors the
t(2;5)(p23;q35) chromosomal aberration, resulting in the
expression of the 80 kDa nucleophosmin-anaplastic lym-
phoma kinase (NPM-ALK) fusion oncoprotein [1–3]. Native
NPM is a nucleolar phosphoprotein, whose functions
include ribosomal RNA assembly, chaperone activities, and
nuclease activity [4]. ALK is a 200 kDa receptor tyrosine
kinase [5] belonging to the insulin receptor superfamily [6].
An N-terminal oligomerization domain within NPM facil-
itates the dimerization of NPM-ALK, leading to autophos-
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phorylation and constitutive activation of the ALK tyrosine
kinase [5]. Activated ALK induces multiple downstream sig-
naling molecules including phospholipase Cg (PLCg) [7],
phosphatidylinositol-3-kinase (PI3K) [8]/RAC protein kinase
(AKT) [9], Janus kinase 3 (JAK3) [10], signal transducer and
activator of transcription 3 (STAT3) [11], and the nonreceptor
protein kinase sarcoma (SRC) [12] which leads to enhanced
cell proliferation, survival, and apoptosis inhibition [13].
The benzoquinone ansamycins geldanamycin (GA) and
derivative, 17-allylamino-17-demethoxygeldanamycin (17-
AAG) elicit antitumor activity in a variety of cancer cell lines,
including ALCL [14, 15]. Heat shock protein 90 (Hsp90) has
been identified as the primary target of GA [16]. Hsp90 is a
highly conserved, ubiquitous molecular chaperone that is
required for the stability and conformational maturation of a
diverse group of client proteins, including components of
signaling pathways exploited by cancer cells for survival and
proliferation [17]. Hsp90 client proteins include receptor ty-
rosine kinases such as human epidermal growth factor
receptor (EGFR) [18] family kinases, breakpoint cluster
region-Abelson (BCR-ABL), and NPM-ALK; cytosolic signal-
ing proteins such as AKT, v-raf-1 murine leukemia viral
oncogene homolog 1 (RAF-1), and inhibitor of nuclear factor
kappa (IKK) as well as cell cycle regulators including cyclin-
dependent kinase 4 (cdk4), polo-like kinase 1 (PLK1), and
survivin [17, 19, 20]. Inhibition of Hsp90 by ansamycins in
ALK-positive ALCL cells results in downregulation of NPM-
ALK protein kinase activity [14] leading to cellular apoptosis
[15]. Clearly, there are multiple cellular targets of Hsp90, yet
the comprehensive effects of Hsp90 inhibition in ALK-posi-
tive ALCL cells are unknown.
Recent developments in multidimensional LC tech-
niques combined with MS/MS have enabled sensitive and
high-throughput detection of low abundance proteins [21].
This technology combined with a cleavable isotope-coded af-
finity tag (cICAT™) approach allows for the global quantita-
tive analysis of proteins in complex mixtures [22]. In this
study, we sought to assess the cellular, biologic, and quanti-
tative proteomic changes occurring in ALK-positive ALCL
cells in response to Hsp90 inhibition by GA. Our results
demonstrate that GA induced G2/M cell cycle arrest and
caspase-3-mediated apoptosis. Moreover, we identified 49
proteins that were upregulated 1.5-fold or greater and 70
proteins downregulated 1.5-fold or greater in GA-treated
cells. Importantly, we identified several proteins involved in
diverse cellular functions, including signal transduction,
DNA metabolism, nucleic acid and protein metabolism, cell
growth and maintenance, and energy pathways. Some of the
downregulated proteins are known to be involved in de-
scribed signaling pathways such as JAK/STAT as well as
pathways previously unreported in ALK-positive ALCL
including mitogen-activated protein kinase (MAPK), WNT,
nuclear factor kappa B (NF-kB), transforming growth factor
b (TGFb), peroxisome proliferator-activated receptor (PPAR),
and integrin signaling. Our studies demonstrate some of the
molecular mechanisms by which Hsp90 inhibition leads to
reduced viability of ALK-positive ALCL cells and reveals cel-
lular proteins whose expression is changed due to GA inhi-
bition of Hsp90.
2 Materials and methods
2.1 Cell culture
The ALK-positive ALCL suspension cell line, SU-DHL-1, was
obtained from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunschweig, Germany). Cells
were cultured in RPMI 1640 (Life Technologies, Grand
Island, NY) supplemented with 15% heat-inactivated FBS
(Nova-Tech, Grand Island, NE), 25 mM HEPES (Invitrogen,
Carlsbad, CA), 2 mM GlutaMAX™ (Invitrogen), and 1%
antibiotic/antimycotic solution (Invitrogen) at 377C in a
humidified atmosphere of 95% oxygen and 5% CO2.
2.2 Cell proliferation assay
Cells were seeded in 6-well plates at a density of 56105 cells/
mL in a final volume of 2 mL and subsequently treated with
DMSO (vehicle) or concentrations of GA (A.G. Scientific,
San Diego, CA) ranging from 0.032 mM through 100 mM in a
volume of 10 mL. For each GA concentration, cultures were
maintained in triplicate. At the end of 6-, 12-, and 24-h,
16104 cells from each control and GA dose were seeded in
96-well plates in triplicate and exposed to 10 mL of WST-1
labeling solution (WST-1 cell proliferation reagent; Roche
Diagnostics, Indianapolis, IN) and subsequently returned to
the incubator for a period of 2 h. The rate of WST-1 cleavage
by mitochondrial dehydrogenases was measured by absorb-
ance at 450 nm using an ELISA plate reader (Molecular De-
vices, Sunnyvale, CA), with a reference wavelength of
600 nm.
2.3 Cell cycle analysis of DNA content
Cells (2 mL; 56105 cells/mL in 6-well plates) were treated
with 10 mM GA for 24 h, harvested after 6, 12, and 24 h, and
prepared for cell cycle analysis as described [23]. Briefly,
16105 control and GA-treated cells were fixed in 70% etha-
nol and stained with 0.1% sodium citrate, 200 mg/mL RNa-
seA, 0.5% NP-40 and 1 mg/mL propidium iodide (PI) and
analyzed using an Epics XL-MCL flow cytometer (Beckman
Coulter, Fullerton, CA). Cell cycle phase distribution was
determined using EXPO32™ software (Beckman Coulter).
Three independent experiments were performed in tripli-
cate.
2.4 Analysis of apoptosis
Cells (2 mL; 56105 cells/mL in 6-well plates) were treated
with 10 mM GA for 24 h, harvested after 6, 12, and 24 h, and
prepared for flow cytometric analysis as described [24].
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Briefly, 16106 control and GA-treated cells were stained with
10 mL annexin V-FITC (Miltenyi Biotechnology, Auburn, CA)
and 10 mL PI (Miltenyi Biotechnology) and analyzed on an
Epics XL-MCL flow cytometer. Three independent experi-
ments were performed in triplicate.
2.5 Caspase-3 activity assay
Cells (2 mL; 56105 cells/mL in 6-well plates) were treated
with 10 mM GA for 24 h. Caspase-3 protease activity was
assessed using the colorimetric Caspase-Glo™ 3/7 colori-
metric assay (Promega, Madison, WI) following the manu-
facturer’s protocol. Briefly, 16104 cells were harvested after
6, 12, and 24 h, seeded in 96-well white-walled plates, and
incubated with 100 mL of caspase-3 substrate, Ac-DEVD-
aminoluciferin. After ambient incubation in the dark for 1 h,
the release of aminoluciferin was measured on a lumin-
ometer (ThermoLabsystems, Waltham, MA). Readings for
blank control was subtracted from experimental readings.
Furthermore, cells were treated with 100 mM caspase-3 in-
hibitor, Z-DEVD-FMK (EMD Biosciences, San Diego) for
15 min followed by 10 mM GA and assay repeated. Three in-
dependent experiments were performed in triplicate.
2.6 Protein isolation and immunoprecipitation
Briefly, cells were collected by centrifugation and washed
twice in PBS. Whole cell lysates were prepared using 500 mL
RIPA lysis buffer (1% NP-40, 0.1% SDS, 0.5% DOC, 20 mM
Tris (pH 7.5), 100 mM NaCl, 0.2% protease inhibitor, and
2 mM activated sodium orthovanadate). After 30-min incu-
bation on ice, samples were centrifuged at 14 000 rpm for
15 min at 47C. Supernatants were recovered and protein
concentrations determined using the Bradford colorimetric
assay with BSA standards (Pierce Chemical, Rockford, IL).
2.7 Immunoblot analysis
For immunoblot analysis, 25 mg of lysate from control and
GA-treated cells were mixed with 10 mL of Laemmli reducing
buffer and heated at 957C for 5 min. Samples were subse-
quently resolved by SDS-PAGE on 4–12% gel and electro-
phoretically transferred to PVDF membranes. Membranes
were blocked for 1 h in blocking solution (5% nonfat milk
diluted in TBS (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, and
0.1% Tween-20)). The following antibodies were used for
immunoblot analysis: mouse polyclonal antibodies against
PARP, p21, and p27; goat polyclonal antibodies against ras
GTPase-activating protein 3 (RARS3), paracellin-1 (PCLN1),
and stanniocalcin-1 (STCN1); and rabbit polyclonal antibody
against actin from Santa Cruz Biotechnology (Santa Cruz,
CA); mouse polyclonal antibodies against Hsp90 and NEMO
(Becton Dickinson Pharmingen, San Diego); rabbit poly-
clonal antibodies against phospho-ALK and ALK (Cell Sig-
naling, Beverly, MA); rabbit polyclonal antibody against ubi-
quitin-specific protease 9 (USP9) (Abgent, San Diego);
mouse polyclonal antibodies against tankyrase (TNKS) and
osteoprotegerin (OPG) and rabbit polyclonal antibodies
against suppressor of cytokine signaling 4 (SOCS4; Acris
Antibodies, Hiddenhausen, Germany). Membranes were
incubated from 1 h at room temperature to 47C overnight
with primary antibodies in TBST containing 3% nonfat dry
milk, washed five times with TBST, and probed with HRP-
labeled secondary antibody at room temperature for 1 h.
After five washes with TBST, immunoreactive bands were
visualized by chemiluminescence (Amersham Biosciences,
Piscataway, NJ). Densitometry was performed using Image J
software (National Institutes of Health (NIH), Bethesda,
MD) and values were normalized to actin controls.
2.8 cICAT labeling of proteins and 3-D LC-MS/MS
SU-DHL-1 control and cells exposed to 10 mM GA were har-
vested after 12 h incubation and prepared for analysis of dif-
ferential protein expression as described in ref. [25] (see Fig. 1
for illustration). Briefly, 400 mg of protein from both samples
were reduced with 2.5 mM Tris (2-carboxyethyl) phosphine
(Sigma) for 1-h at 377C. Isotope labeling was performed by
mixing 1 U of light (control sample) or heavy (GA-treated
sample) cleavable cICAT reagent with protein samples, fol-
lowing manufacturer’s protocol (Applied Biosystems).
Labeled proteins from control and treated samples were
mixed and dialyzed against 500 mL of urea buffer (2 M urea,
10 mM Tris, pH 8.5) three times for 1-h each at room tem-
perature using a 3.5 kDa cutoff dialysis cassette (Pierce). The
dialyzed protein mixtures were then diluted two-fold with
10 mM Tris, pH 8.5, before digestion with 10 mg of modified
trypsin (Promega) overnight at 377C. The peptide mixture
was then acidified to pH3.0 by adding TFA before loading
onto the cation exchange column. The 3-D liquid chromato-
graphic separation of peptides was performed by first, strong
cation-exchange (SCX) chromatography using a 3.6 mm6
20 cm polysulfoethyl A column (Poly LC, Columbia, MD) at a
flow rate of 400 mL/min with 35 fractions collected
(800 mL/fraction). A two-step linear buffer gradient was used:
5% buffer B and 95% buffer A to 25% buffer B and 75%
buffer A for 50 min followed by 25% buffer B and 75% buffer
A to 100% buffer B for 18 min (buffer A: 20 mM KH2PO4,
25% ACN pH 3.0; buffer B 350 mM KCL in buffer A pH 3.0).
Next, 35 fractions collected from the offline SCX chroma-
tography were further washed and purified by avidin affinity
chromatography (Applied Biosystems) to enrich for cysteine
containing (cICAT-labeled) peptides followed by drying and
cleaving of eluted peptides. Finally, a 15 mL aliquot of each
sample was analyzed by automated nanoflow RP LC/MS
using the LCQ Deca XP IT mass spectrometer (Thermo-
Finnigan, San Jose, CA). Digested peptides were injected by
an autosampler, using an ACN gradient (0–60% B in
120 min; A = 5% ACN with 0.4% acetic acid and 0.005%
HFBA) through a RP column (75 mm id fused silica packed
in-house with 10 cm of 5 mm C18 particles) to elute the pep-
tides at a flow rate of ,200 nL/min into the mass spectrom-
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Figure 1. cICAT strategy to isolate and identify differentially
expressed proteins in GA-treated cells relative to control. Cells
were in the presence of 1% DMSO (control) or 10 mM GA for 12 h.
Total cellular protein was precipitated under reduced conditions.
Total protein from control cells was labeled with the light cICAT
reagent (black circle) and protein from GA-treated cells labeled
with the heavy cICATreagent (gray circles). Samples were mixed,
proteolyzed in trypsin, and subjected to avidin affinity chroma-
tography. Isolated cICAT-labeled peptides were subjected to LC-
MS/MS to quantitate and identify differentially expressed pro-
teins.
eter. An electrospray voltage of 1.8 kV was used with the ion
transfer tube temperature set to 2007C. Peptide analysis was
performed using data-dependent acquisition of one MS scan
(600–2000 m/z) followed by MS/MS scans of cICAT peptide
pairs triggered by the isotope tag mass difference of 9.0 amu.
To obtain better peptide coverage, dynamic exclusion was set
to a repeat count of 3, with the exclusion duration of 5 min.
2.9 Data analyses
The MS/MS acquired data were searched using the
SEQUEST algorithm in Bioworks 3.1 (ThermoFinnigan)
against human amino acid sequences in the 9.23.2004
download of the NCBI nr.fasta protein database with 191 136
entries. Protein search parameters included a precursor
peptide mass tolerance of 6 0.7 amu and fragment mass
tolerance of 6 0.1 amu. To account for the isotope label, sta-
tic modification of cysteine was set to 227.13 and differential
modification of cysteine set as 9.0. The search was con-
strained to tryptic peptides with one missed enzyme cleavage
allowed. The peptide matching criteria of a cross correlation
score (Xcorr).1.2 for 11 peptides, .2.2 for 12 peptides, and
.3.2 for 13 peptides, and a delta correlation score
(DCn).0.100 was used as a threshold of acceptance. cICAT
protein quantification was performed using XPRESS™ soft-
ware (Thermo) which automatically calculates the relative
abundance of light and heavy cICAT-labeled peptide as a
ratio of light database containing both forward and reverse
amino acid sequences for each protein entry. The total num-
ber of proteins identified with reverse sequence entries is
then multiplied (26) to compensate for doubling the size of
the database. Overall, the predicted false positive rate for
protein identification by LC-MS/MS was 7.1%.
Differentially expressed proteins were further analyzed
using the Ingenuity™ Pathways Analysis (Ingenuity, Moun-
tain View, CA) web-based application software tool and
Bioinformatics Harvester database. Protein accession num-
bers and corresponding cICAT expression values were saved
into the Ingenuity Systems template.xls file. Files were sub-
mitted on-line for analysis and comparison to the Ingenuity
gene/protein interaction knowledge base (http://www.
ingenuity.com/). The results for the pathways and protein
interactions were summarized and interaction network im-
ages generated with respect to putative canonical pathways.
Individual proteins were submitted to the Bioinformatics
Harvester database (http://harvester.embl.de/) and protein
functional characteristics analyzed.
3 Results
3.1 GA reduces cell viability
In order to establish the proteome-wide changes induced by
GA in ALK-positive ALCL cells, we first sought to assess the
effects of GA on cell viability.
Previous studies have demonstrated that ansamycins tar-
get Hsp90 and inhibit its function as a molecular chaperone.
To determine if GA induced similar effects on ALK-positive
ALCL cells, we cultured the NPM-ALK-positive ALCL cell line,
SU-DHL-1, with increasing concentrations of GA up to 24 h
and measured cell viability using the WST-1 assay. As shown
in Fig. 2A, the most effective drug concentration was between
4 and 20 mM, with IC50 values of 10.9, 13.3, and 13.6 mM at 6,
12, and 24 h, respectively. There was no statistically signifi-
cant reduction in viability between 20 and 100 mM demon-
strating the maximum effects of the drug. We subsequently
treated SU-DHL-1, Karpas299, and DEL cells in the presence
or absence of 10 mM GA and measured cell viability at 6, 12,
and 24 h. Figure 2B illustrates the effects of GA on cell viabil-
ity in a time-dependent manner. Based on our preliminary
dose-dependence results, we selected a concentration of
10 mM for subsequent experiments.
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Figure 2. (A) GA reduces cell viability. Cells were cultured in the presence of 1% DMSO or various concentrations of GA for the indicated
times and cell viability assessed by WST-1 reduction assay. Concentrations of GA are listed on the x-axis. Viability as percent of control is
listed on the y-axis. Results are expressed as the mean of three independent experiments performed in triplicate 6 SDs. Data are normal-
ized to DMSO control. (B) GA induces G2/M cell cycle arrest. Control and GA-treated cells were harvested and fixed after 6, 12, and 24 h
incubation. Cellular DNA content was determined by flow cytometric analysis after RNase treatment and PI staining. Time and DNA content
are denoted on the x-axis and % cells are denoted on the y-axis. Results are expressed as the mean of three independent experiments,
performed in triplicate 6 SDs. (C) GA induces apoptosis. Control and GA-treated cells were harvested after 6, 12, and 24 h and stained with
annexin V-FITC/PI. Cellular apoptosis was determined by flow cytometric analysis. Annexin V-FITC staining is denoted on the x-axis. PI
staining is denoted on the y-axis. Left panels illustrate the staining patterns of control for each time point. Right panels illustrate the
staining patterns of GA-treated cells for the same time points. The percent of cells in each particular quadrant represents the mean of three
independent experiments. SDs were within 5% of the mean. (D) GA-induced apoptosis is mediated by caspase-3. Control and GA-treated
cells were harvested after 6, 12, and 24 h. Caspase-3 activity was determined by luminescence detection of caspase-3 substrate cleavage.
Time is denoted on the x-axis. The increase in caspase-3 luminescence as a percent of Z-DEVD-FMK control is denoted on the y-axis.
Results are expressed as the mean values of three independent experiments, performed in triplicate 6 SDs.
3.2 GA induces G2/M cell cycle arrest
We investigated the effects of GA on cell cycle phase dis-
tribution to determine whether cell viability reduction was
caused by disruption of cell cycle-related events. Cells cul-
tured in 10 mM GA were harvested at the indicated times,
stained with PI, and subjected to cell cycle analysis. The
percent of cells in G1 were unchanged at 6 and 12 h, but
were reduced by 10.8% after 24 h, relative to control
(Fig. 2C). A reduction of cells in S-phase was seen at 12 and
24 h by 9.9 and 18%, respectively, compared to control. In
contrast, cells in G2/M increased by 10.4 and 24.2% after 12
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and 24 h, compared to control. These data suggest that the
reduction of cell viability is due to a block in the G2/M
transition.
3.3 GA induces caspase-3-mediated apoptosis
To further analyze the effects of GA on cell viability, we per-
formed time-course flow cytometric analysis of annexin V-
FITC/PI stained cells. Figure 2D illustrates the time-de-
pendent increase in apoptotic cells in response to GA after 6,
12, and 24 h. The fraction of early and late apoptotic cells
(annexin V-positive/PI negative and annexin V-positive/PI-
positive) increased by 2.3% at 6 h, 7.7% at 12 h, and 36.5% at
24 h, respectively, relative to control. To evaluate the mech-
anism of GA-induced apoptosis, we analyzed caspase-3 ac-
tivity. As shown in Fig. 2E, GA induced a time-dependent
increase in caspase-3 activity by 1.3, 2.0, and 10.7% at 6, 12,
and 24 h, respectively, relative to control. Furthermore, cas-
pase-3 activity was completely inhibited by the caspase-3 in-
hibitor Z-DEVD-FMK at all time points. These results
demonstrate that GA induces caspase-3-mediated apoptosis.
3.4 Effects of GA on NPM-ALK, Hsp90, cell cycle
regulatory proteins, and apoptosis regulatory
proteins
To examine the underlying mechanisms by which GA arrest-
ed cells in G2/M and induced caspase-3-mediated apoptosis,
we performed immunoblot analysis to determine relative
expression of phosphorylated and nonphosphorylated NPM-
ALK, Hsp90, p21CIP1, p27KIP1, and PARP. After 12 h drug
treatment, the expression of both nonphosphorylated and
phosphorylated NPM-ALK expression was markedly reduced
in GA-treated cells (Fig. 3). In contrast, expression of Hsp90
remained unchanged. While expression of the Cdk2 inhibi-
tor, p21CIP1 was unchanged, the expression of the Cdk4 in-
hibitor, p27KIP1 was induced in GA-treated cells. Moreover,
PARP underwent cleavage into its 85 kDa fragment with GA
treatment, consistent with apoptosis. The levels of actin
remained unchanged.
3.5 MS/MS analysis of cICAT-labeled peptides
We sought to survey the proteomic changes induced by GA
inhibition of Hsp90 using cICAT- LC-MS/MS. Top protein
database search hits from SEQUEST were summarized
using BioWorks 3.1 and the relative quantification calculated
using XPRESS. Figure 4 displays an example of the MS-full
scan and MS/MS scan for the cICAT-labeled peptide
sequence corresponding to SOCS4. Examination of the data
from 35 individual SCX fractions resulted in a total of 2921
peptides identified, which were matched to 1129 known
NCBI database entries and 314 unique proteins. Of the 176
cICAT-labeled peptides, 119 were differentially expressed by
1.5-fold or greater at 12 h. Over- and underexpressed proteins
Figure 3. GA inhibition of Hsp90 influences expression of a variety
of proteins. Total cell lysate was extracted from control and GA-
treated cells after 12 h and proteins separated by SDS-PAGE.
Immunoblots were probed with antiphospho-ALK (1:1000), anti-
NPM-ALK (1:1000), anti-Hsp90 (1:1500), anti-p21 (1:500), anti-p27
(1:500), anti-PARP (1:1500), and antiactin (1:500); incubated at
room temperature for 1 h (Hsp90, p21, p27, PARP, and actin) or
overnight at 47C (phospho-ALK and NPM-ALK), followed by prob-
ing with respective horseradish-peroxidase conjugated secondary
antibodies and visualized by chemiluminescence. Actin served as
a loading control. Protein sizes are listed left of each immunoblot.
were categorized by biological process (Table 1). A large
number of the differentially expressed proteins were down-
regulated (59%) in response to GA.
The Bioinformatics Harvester database (http://harvester.
embl.de/) was used to perform analysis of protein functional
characteristics using the 1.5-fold threshold. Seventy-seven
percent of the proteins identified and quantified have known
functions, while 23% were assigned to the hypothetical cate-
gory. Furthermore, 84% of the identified proteins were
assigned to nuclear, cytoplasmic, membranous, or extra-
cellular locations while the subcellular locations of the
remaining 16% are unknown. Figure 5A illustrates localiza-
tion of overexpressed proteins and Fig. 5B illustrates locali-
zation of underexpressed proteins in GA-treated cells. Anal-
ysis of localization demonstrated the majority of proteins
exist in the nucleus and cytoplasm (67% of overexpressed
and 75% of underexpressed).
Analysis of biological pathways of differentially expres-
sed proteins using the Ingenuity Pathways Analysis tool
revealed deregulated proteins involved in a variety of path-
ways, including integrin, estrogen receptor, MAPK, JAK/
STAT, PPAR, and NF-kB signaling as well as those involved
in ubiquitin-mediated proteolysis and cell cycle regulation.
Several of the proteins are involved in multiple functions
such as the versus heavy [25].
The false-positive error rate for protein identifications
was calculated using the composite target/decoy database
method [26]. Acquired MS/MS spectra were searched against
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Table 1. Differentially expressed proteins of 1.5-fold over- and underexpressed, categorized by biological function
Name Description NCBI Fold Peptides Xcorr Charge
state
Cell signaling
Overexpressed MAP4K1 Mitogen-activated protein kinase
kinase kinase kinase 1
6005810 25.0 -.SSSLGIPDADC*CR.- 1.38 1
WNT10B Wingless-type MMTV integration
site family, member 10B
precursor
16936522 8.3 -.C*HGTSGSCQFK.- 2.58 2
CLK2 Dual specificity protein kinase
CLK2 (CDC-like kinase 2)
1705919 3.6 -.VVQC*VDHRRGGAR.- 2.62 2
RASA3 Ras GTPase-activating protein 3
(GAP1(IP4BP))
13959562 2.8 -.ALYIQANNC*VEAK.- 2.53 2
PLEKHA2 Pleckstrin homology domain-
containing protein family A
member 2
48474645 2.4 -.TPFC*FVINALSQR.- 2.54 2
RAPGEF6 Rap guanine nucleotide
exchange factor 6
34395686 2.3 -.LLNIAC*AAKAKWR.- 2.52 2
MAPK14 Mitogen-activated protein
kinase kinase kinase 14
4505397 2.2 -.LISPLQC*LNHVWK.- 1.23 1
STC1 Stanniocalcin 1 4507265 2.1 -.ESLKC*IANGVTSK.- 2.12 1
IL1R1 Interleukin-1 receptor, type I
precursor
4504659 1.9 -.QC*GYKLFIYGR.- 2.05 1
ARHGAP20 Rho GTPase-activating
protein 20
25535895 1.8 -.VSLLIQFLIENC*LR.- 1.48 1
SMAD5 SMAD, mothers against DPP
homolog 5; Dwfc
47778925 1.8 -.PLDIC*EFPFGSK.- 2.65 2
Underexpressed GRIN2D N-methyl-D-aspartate receptor
subunit 2-D precursor;
estrogen receptor
4504131 7.1 -.CC*KGFC*IDILKR.- 3.00 2
IL26 Interleukin 26 precursor 8923756 7.1 -.C*GLLLVTLSLAIAK.- 2.59 2
ZP4 Zona pellucida glycoprotein 4
preproprotein; zona
pellucida B protein
10863987 7.1 -.KLLKC*PMDLLAR.- 2.55 2
PTK2B Protein tyrosine kinase 2 b
isoform a; (PTK2B) cell
adhesion kinase
27886584 6.7 -.PTC*LAEFKQIRSIR.- 1.45 1
PI-G PLD Similar to phosphatidylinositol-
glycan-specific




5803181 5.0 -.ELC*EKAIEVGRENR.- 1.38 1
PDC Phosducin isoform a; G b g
binding protein
32967591 4.6 -.FC*KIKASNTGAGDR.- 2.62 2
RAD17 Checkpoint protein, involved in
the activation of the DNA
damage
6324944 4.0 -.DYPGIVIEVC*MLEK.- 2.56 2
CBLC Signal transduction protein
CBL-C (SH3-binding protein
CBL-C)
46397888 3.6 -.APAHTFWRESC*GAR.- 2.58 2
GRB7 Growth factor receptor-bound
protein 7
4885355 2.5 -.PHVVKVYSEDGAC*R.- 1.38 1
RPS6KB1 Ribosomal protein S6 kinase,
70 kDa, polypeptide 1
4506737 2.5 -.IRPEC*FELLRVLGK.- 2.19 1
SOCS4 Suppressor of cytokine
signaling 4 (SOCS4)
20178095 2.4 -.PTNSEETC*IKMEVR.- 1.90 1
ANAPC4 Anaphase promoting complex
subunit 4 (APC4)
37537862 2.4 -.SMNQAIC*IPLYR.- 2.79 2
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Table 1. Continued
Name Description NCBI Fold Peptides Xcorr Charge
state
IKBKG** Inhibitor of kappa light
polypeptide gene enhancer
in B-cells (NEMO)
4504631 2.4 -.C*QQQMAEDKASVK.- 2.54 2
T3JAM TRAF3-interacting JNK-activating
modulator
13435127 2.2 -.C*RPNVTTCRQVGK.- 1.40 1
MAK** Male germ cell-associated kinase 11496279 2.1 -.KFYSWDEC*MNLR.- 2.52 2
PDE5A Phosphodiesterase 5A isoform 1;
cGMP-binding cGMP-specific
4505667 2.0 -.VHTIPVC*KEGIR.- 1.31 1
RAC3 Ras-related C3 botulinum toxin
substrate 3
4826962 2.0 -.HHC*PHTPILLVGTK.- 1.41 1
TNFRSF11B Human osteoprotegerin (OPG)
protein
2072185 1.8 -.VGAEDIEKTIKAC*K.- 1.57 1
DKK2 Dickkopf homolog 2; Dickkopf
gene 2
7657023 1.7 -.GKNLGQAYPC*SSDK.- 2.63 2
1 Myelin oligodendrocyte
glycoprotein isoform 2
45580732 1.6 -.FSDEGGFTC*FFR.- 2.58 2
DNA metabolism
Overexpressed ZNF297 Zinc finger protein 297
(BING1 protein)
23396973 9.1 -.PFDCPVC*NKKFK.- 1.34 1
CTCF CCCTC-binding factor (zinc
finger protein)
5729790 2.6 -.PHKC*HLCGRAFR.- 2.11 1
OIP106 106 kDa O-GlcNAc transferase-
interacting protein
13124654 1.7 -.YFLLC*AERVGQMTK.- 1.29 1
THOC1 Nuclear matrix protein p84 4826882 1.7 -.QIEC*DSEDMKMRAK.- 2.13 1




4507613 4.2 -.ELLEAC*RNGDVSR.- 2.78 2
HILS1 Spermatid-specific linker
histone H1-like protein
34850057 4.0 -.GTC*KYVSLATLKK.- 2.52 2
1 Similar to cofactor required
for Sp1 transcriptional
activation
38086032 3.9 -.TDALKC*RVALSPK.- 1.51 1
ZNF324 Zinc finger protein 324
(Homo sapiens)
7657693 3.1 -.PFRCVDC*GKAFAK.- 2.00 1
SNRP70 U1 small nuclear ribonucleo-
protein 70 kDa
29568103 3.0 -.HHNQPYC*GIAPYIR.- 1.28 1
SRrp35 35 kDa SR repressor protein
(SRrp35)
47606193 2.8 -.HSDSIARSPC*KSPK.- 2.50 2
ZNF516 Zinc finger protein 516 14548318 2.7 -.GSFDHGC*HICGRR.- 1.43 1
SIX5 Homeobox protein SIX5 46396941 2.5 -.AC*YRGNRYPTPDEK.- 1.85 1
JRK Jerky protein homolog 27805484 2.1 -.QPC*FSAQEVGQLR.- 2.57 2
POLRD3 RNA polymerase III 53 kDa
subunit RPC4
4502437 1.9 -.LVC*SPDFESLLDHK.- 1.68 1
Protein metabolism
Overexpressed PSMD9 26S proteasome non-ATPase
regulatory subunit 9
12230943 5.6 -.GLLGC*NIIPLQR.- 2.65 2
USP9X Ubiquitin specific protease 9 11641423 5.6 -.WYKFDDGDVTEC*K.- 1.56 1
ADAMTS12 A disintegrin-like and metall-
oprotease
13569928 4.4 -.ATFC*DPETQPNGR.- 2.55 5
AARS Alanyl-tRNA synthetase 4501841 3.7 -.AVYTQDC*PLAAAK.- 2.01 1
PSMD7 26S proteasome regulatory
chain, p40
1085272 2.1 -.YC*PNSVLVIIDVK.- 2.59 5
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Table 1. Continued
Name Description NCBI Fold Peptides Xcorr Charge
state
Underexpressed MRPS15 Mitochondrial ribosomal protein
S15; 28S ribosomal protein S15
16554611 2.7 -.KALC*IRVFQETQK.- 1.69 1
PSMD2 Proteasome b 2 subunit;
proteasome subunit,
beta-type, 2
4506195 2.7 -.AVELLRKC*LEELQK.- 1.80 1
CAPN5 Calpain 5 37577157 2.2 -.NEFWC*ALVEKAYAK.- 2.07 1
SACS Sacsin 13124523 2.0 -.VCQFGALC*SLQGR.- 1.62 1
PRSS15 Endopeptidase La homolog
(EC 3.4.21.-) precursor
1362755 2.0 -.AGVTC*IVLPAENKK.- 2.55 2
VCIP135 Valosin-containing protein (p97) 36029914 1.8 -.PICC*AWSSSGR.- 2.54 2
Cell growth
Overexpressed PCLN1 Claudin 16; paracellin-1 5729970 2.6 -.RPVFSHC*QVPETQK.- 1.35 1
DRP2 Dystrophin-related protein 2 4503393 2.6 -.HFVPSAGADSETHC*.- 2.66 2
AKAP6 A-kinase anchor protein 6 13431309 1.8 -.TLTC*EENLLNLHEK.- 1.85 1
SYNE2 Nesprin 2 (Nuclear envelope
spectrin repeat protein 2)
29839588 1.7 -.PVVYDVC*DDQEIQK.- 1.21 1
CRYBA4 Crystallin, beta A4 4503059 1.7 -.MTLQC*TKSAGPWK.- 1.38 1
LZTS1 Leucine zipper, putative tumor
suppressor 1
10440566 1.5 -.GLELEVC*ENELQRK.- 1.87 1
Underexpressed MCPH1** Estrogen receptor beta 7441774 5.3 -.CYEVGMVKC*GSR.- 1.66 1
XRCC4 X-ray repair cross comple-
menting protein 4 isoform 2
12408647 2.0 -.C*VSAKEALETDLYK.- 2.12 1
MAP1A Microtubule-associated protein
1A (proliferation-related)
19861596 1.6 -.PCC*YIFPGGR.- 2.06 1
DNAH9 Ciliary dynein heavy chain 9 12643822 1.5 -.LNWPHMIC*EDVRR.- 1.96 1
TFF2 Trefoil factor 2 precursor;
spasmolytic protein 1;
spasmolysin
4885629 1.5 -.QESDQC*VMEVSDRR.- 3.12 2
Metabolism
Overexpressed AKAT1 Acetyl-Coenzyme A acetyltrans-
ferase 1 precursor
4557237 5.3 -.IHMGSC*AENTAKK.- 2.68 2
SKD3 Suppressor of potassium
transport defect 3
13540606 2.9 -.FDTKC*LAAATWGR.- 2.70 2
PDE6C Cone cGMP-specific 30,50-cyclic
phosphodiesterase alpha0-
subunit
1705960 2.6 -.LNVDVIDDC*EEK.- 2.50 2
FTCD Formiminotransferase
cyclodeaminase
11140815 2.3 -.MGALDVC*PFIPVR.- 2.53 1
1 Glycosylphosphatidylinositol 1
homolog
31981380 1.7 -.SKLSTC*EQLHHRLK.- 2.18 2
BCHE Butyrylcholinesterase precursor 4557351 1.6 -.LTGC*SRENETEIIK.- 2.54 2
Underexpressed UQCRH Ubiquinol-cytochrome c
reductase hinge protein
5174745 4.6 -.ERLELC*DERDSSR.- 2.69 2
ACACB Acetyl-CoA carboxylase (EC
6.4.1.2)
542750 2.7 -.YRITIGNKTC*VFEK.- 1.31 1
Transport
Overexpressed STX17 Syntaxin 17 8923604 3.5 -.LTSSC*PDLPSQTDK.- 2.57 2
SCN1A Sodium channel protein type I
alpha subunit




23503045 2.2 -.DNGMQKC*SHIPGRR.- 1.22 1
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Table 1. Continued
Name Description NCBI Fold Peptides Xcorr Charge
state
Underexpressed ADFP Adipose differentiation-related
protein; adipophilin
34577059 1.9 -.LEPQIAVANTYAC*K.- 2.77 2
Immune response
Overexpressed TNFRSF6B Helicase-like protein NHL
isoform 2
14790174 3.3 -.NTSYRPKVC*VLGSR.- 2.71 2
HLA-B HLA-B protein 2118848 2.2 -.MYGC*DLGPDGRFLR.- 1.81 1
Hypothetical
Overexpressed SFRS14 KIAA0365 7512968 10.0 -.AWLVSSGC*PLQVK.- 2.60 2
1 SI:zC237L4.5 novel protein
similar to human procollagen
33468666 7.1 -.PHVDEHQFC*GGK.- 2.04 1
1 DKFZp762E1312.1 11283475 5.0 -.C*LPKSDSSSSLPK.- 1.87 1
1 DKFZp434L243.1 7512652 4.4 -.PPGGHSNLAC*ALKK.- 2.52 2
TRIM14 Tripartite motif protein TRIM14
isoform alpha
15208663 4.2 2.51 2
TTC4 Tetratricopeptide repeat
domain 4
39652618 3.9 -.AIIRGALC*HLELK.- 2.63 2
SOSTDC1 DKFZp564D206.1 7512729 3.3 -.SSQEWRC*VNDK.- 2.07 1
DLG7 KIAA0008 3183208 3.2 -.NVETKPDKGISC*K.- 1.55 2
1 KIAA0590 7513032 2.1 -.RPLRDFVGLEDC*DK.- 2.13 1
Underexpressed GTF2H4 XP_378195 42657571 20.0 -.LYGHPATC*LAVFR.- 2.63 2
WDR17 WD-repeat protein 17 47606182 4.4 -.EGILC*SGSDDGTVR.- 2.51 2
1 DKFZp434M183.1 7512659 4.0 -.DVVC*TCSLKNWR.- 2.15 1
FGL2 Fibrinogen-like 2; fibrinogen-like
protein 2; fibroleukin
5730075 2.9 -.DVC*PVRLESRGK.- 2.08 1
1 19.0 kDa early protein 139989 2.6 -.ITKNTFSTASC*GK.- 1.82 1
HERPUD1 Homocysteine-inducible, ER
stress-inducible
7661870 2.5 -.AC*YRGNRYPTPDEK.- 1.28 1
1 Leucine-rich repeat LGI family,
member 4
21281673 2.3 -.PEEELPAASVVSC*K.- 1.60 1
1 KIAA0232 30923325 2.3 -.PVC*LQEIMTVWNK.- 1.26 1
1 SI:zC255F14.1 (novel protein
similar to human RIM binding
protein)
33468681 2.2 -.PPC*WSSSSSRQTTK.- 1.66 1
PGLYRP4 Peptidoglycan recognition
protein I-beta precursor
38604973 1.9 -.TSLKKAC*PGVVPR.- 1.79 1
1 Interleukin-14 precursor 627504 1.9 -.PARLC*LGTPFLRSR.- 2.50 2
ANKMY1 Ankyrin repeat and MYND
domain containing protein 1
30912747 1.9 -.ESQWDPTWLYLC*K.- 1.95 1
HES1 Human HES1 protein 5031691 1.9 -.NLSTFAVDGKDC*K.- 2.79 2
KIAA1199 KIAA1199 protein 38638698 1.6 -.FAFC*SMKGCERIK.- 1.40 1
INFA5 Interferon alpha-G 87983 1.6 -.MC*DLPQTHSLSNRR.- 2.14 1
EGFL3 Multiple EGF-like domain
protein 3
46395624 1.5 -.CVC*HAGYELGADGR.- 1.30 1
SDF2 Stromal cell-derived factor 2
precursor (SDF-2)
21542241 1.5 -.C*GQPIRLTHVNTGR.- 1.84 1
C7orf28A DKFZp586I1023.1 7512900 1.5 -.KLC*ATQFNNIFFLD.- 2.01 1
1 DKFZp434K1772.1 7512635 1.5 -.C*PPQLRPSR.- 2.58 2
Cells were in the presence of 1% DMSO (control) or 10 mM GA for 12 h and total cellular protein precipitated. Samples were cICAT labeled
and analyzed by LC-MS/MS. Identified peptides of 1.5-fold over- and underexpressed were searched against the Bioinformatics Harvester
database for biological function. Proteins were categorized by biological function (over- or underexpressed) and listed are protein names,
description, NCBI GI number, fold change, identified peptides, crosscorrelation score, and charge state.
Known Hsp90 clients or interacting proteins are designated **, cICAT labeled cysteines are designated *, and unnamed proteins are
designated 1.
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Figure 4. Identification of SOCS4 by LC-MS/MS.
MS full scan and data-dependent MS/MS scan
showing sequencing of the cICAT tryptic peptide
R.PTNSEETC*IKMEVR, which identified SOCS4
as underexpressed 2.44-fold. Peptide sequenc-
ing is indicated by matching b-ion (red) and y-ion
(blue) fragments.
a protein enzyme USP2, which was identified as being
involved in ubiquitin-mediated proteolysis, MAPK signaling,
and PPAR signaling.
Analysis of proteins further implicated those involved in
JAK/STAT (underexpressed: IL26, CBLC, and SOCS4), WNT
(overexpressed: WNT10B; underexpressed: DKK2, NEMO,
and RAC3), MAPK (overexpressed: IL1R1, MAP4K1,
MAPK14, RASA3, and Rap guanine nucleotide exchange
factor (RAPGEF6); underexpressed: NEMO and RAC3), NF-
kB (underexpressed: TNFRSF11B and NEMO), and TGFb
(underexpressed: RPS6KB1 and SMAD5) pathways.
3.6 Immunoblot validation of differentially expressed
proteins
We selected eight differentially expressed proteins identified
by cICAT-LC-MS/MS to validate changes in expression by
immunoblot. Importantly, relative differences between
cICAT and immunoblot were within 50% of each other.
Immunoblot analysis demonstrated that USP9, ras GTPase-
activating protein 3 (GAP1), PCLN1, and STCN were over-
expressed in GA-treated cells relative to control by 5.6-, 2.8-,
2.6-, and 2.1-fold (cICAT), respectively. Proteins that were
underexpressed in GA-treated cells including tankyrase,
SOCS4, IKKk (NEMO), and OPG were also confirmed by
immunoblot analysis and were reduced by 4.2-, 2.4-, 2.4-, and
1.8-fold (cICAT), respectively, relative to control. Figure 6
illustrates the respective overexpressed proteins (left panels)
and underexpressed proteins (right panels) with corre-
sponding cICAT and densitometry ratios.
4 Discussion
ALK-positive ALCLs are most commonly associated with the
t(2;5)(p23;q35) chromosomal aberration, resulting in
expression of the chimeric NPM-ALK oncoprotein [1–3].
Survival of ALK-positive ALCL cells is mediated by the acti-
vation of signaling pathways [7–12] that inhibit apoptosis and
promote cell proliferation [13]. Vital to the survival of these
cells is the function of the chaperone protein Hsp90, which
enhances the stability of the NPM-ALK protein [14, 15].
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Figure 5. Cellular localization of proteins identified by MS/MS in
upregulated (A) and downregulated (B) proteins. Protein from
control and cells exposed to 10 mM GA were harvested after 12 h
incubation and cICAT-labeled followed by LC-MS/MS analysis.
Peptides were searched against the NCBI database for localiza-
tion. Proteins overexpressed (A) or underexpressed (B) were
categorized by cellular localization.
Figure 6. Immunoblot validation of differentially expressed pro-
teins as identified by LC-MS/MS. Total cell lysate was extracted
from control and GA-treated cells after 12 h and proteins sepa-
rated by SDS-PAGE. Immunoblots were probed with anti-USP9
(1:1000), anti-GAP1 (1:300), anti-PCLN (1:300), anti-STCN (1:300),
anti-tankyrase (1:1000), anti-SOCS-4 (1:1000), anti-NEMO
(1:1000), anti-OPG (1:500), and anti-actin (1:500). Immunoblots
were then incubated at room temperature for 1 h followed by
probing with respective HRP-conjugated secondary antibodies
and visualized by chemiluminescence. The left panels depict the
overexpressed proteins as identified by LC-MS/MS in control and
cells exposed to 10 mM GA. The right panels depict the under-
expressed proteins as identified in the same samples. Both
cICAT- and densitometry fold-change is listed below the 10 mM
GA lanes. Actin served as a loading control.
Hsp90 assists in the functional maturation of a diverse
group of proteins, particularly those involved in cancer-relat-
ed signaling [16]. GA binds to the N-terminus ATP-binding
domain of Hsp90, thereby preventing Hsp90 from perform-
ing its chaperone duties [27]. Inhibition of Hsp90 by ansa-
mycins reduces the expression levels of its client proteins by
subjecting them to ubiquitin-mediated proteasomal degra-
dation [14, 28]. GA and its analog, 17-AAG, have been shown
to reduce the expression of NPM-ALK and result in sub-
sequent cellular apoptosis [14, 15]. However, the compre-
hensive proteomic changes induced by the drug are currently
unknown. The results of our quantitative proteomic study
demonstrate that the effects of GA on ALK-positive ALCL
cells are diverse and affect proteins involved in cell signaling,
DNA metabolism, protein metabolism, cell growth, and
transport.
In this study, we demonstrate that the NPM-ALK-positive
ALCL cell line, SU-DHL-1, is sensitive to GA inhibition of
Hsp90. The display of both increased caspase-3 activity
(Fig. 2D) and cleavage of PARP (Fig. 3) indicate that Hsp90
inhibition by GA induces the mitochondria-mediated apop-
totic pathway, in line with other studies using GA in a variety
of cell lines [29–32]. Furthermore, GA treatment resulted in
the downregulation of both the native NPM-ALK and phos-
pho-NPM-ALK (Fig. 3), in agreement with previous studies
using 17-AAG in ALK-positive ALCL cells [14, 15]. These
results reinforce the critical role of NPM-ALK in the survival
of these cells [14, 15]. We further showed that the expression
of Hsp90 itself did not change in response to GA treatment
(Fig. 3), suggesting that GA does not inhibit expression of
Hsp90 [33].
Cell cycle analysis revealed that GA induced G2/M cell
cycle arrest (Fig. 2B). While this observation contradicts
other studies that report G1 arrest in cells exposed to 17-AAG
[14, 15], GA has been shown to induce G2/M arrest in ery-
throleukemic cells through inhibition of Cdc2 and induction
of p27Kip1 [34] and other G2/M regulators [17]. The induction
of p27Kip1 but not p21Cip1 (Fig. 3) observed in our studies is
consistent with G2/M cell cycle arrest.
Analysis of the proteome of GA-treated cells demon-
strated that numerous proteins that perform diverse cellular
functions are affected by Hsp90 inhibition (Table 1). Proteins
known to be involved in signaling pathways important for
survival of ALK-positive ALCL cells include PI3K/AKT [8, 9],
JAK/STAT [10, 11], and PLCg [7]. Our quantitative proteomic
analysis revealed differential expression of proteins belong-
ing to multiple signaling pathways including those in the
MAPK (overexpressed: MAP4K1, RASA3, RAPGEF6,
MAPK14, and IL1R1; underexpressed: NEMO and RAC3),
JAK/STAT (underexpressed: IL26, CBLC, and SOCS4), WNT
(overexpressed: WNT10B; underexpressed: RAC3, NEMO,
and DKK2), NF-kB (overexpressed: IL1R1; underexpressed:
NEMO and TNFRSF11B), and TGFb (underexpressed:
RPS6KB1 and SMAD5) pathways. Because of the roles of
these pathways in survival signaling, we were surprised to
identify 41% overexpressed proteins. However, because
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samples were analyzed after 12 h drug exposure, these
results may be indicative of secondary and tertiary effects of
the drug on MAPK signaling. For example, MAP4K1 has
been reported to influence FAS-mediated apoptosis and cas-
pase-3-mediated cleavage of MAP4K1 at Asp385 converting
MAP4K1 from an activator of the transcription factor NF-kB
into an NF-kB inhibitor, thus favoring apoptosis [35, 36].
The role of Hsp90 as a molecular chaperone involved in
the folding of protein kinases has been well described [18, 37,
38]. Our study also showed that GA treatment resulted in
decreased expression of many protein kinases (PTK2B,
RPS6KB1, and MAK), including serine/threonine kinases
(RPS6KB1 and MAK), and tyrosine kinase (PTK2B) and
NPM-ALK. Whether these protein kinases are downstream
targets of NPM-ALK and/or client proteins of Hsp90
remains to be determined.
Several Hsp90 client proteins and interactors were found
to be differentially expressed by quantitative proteomics and
validated by immunoblot analysis, including NPM-ALK,
STIP1 [39], NEMO [40], MAK [41], and MCPH1 [42]. Impor-
tantly, all of the identified Hsp90 clients and interactors were
underexpressed in response to GA, which provides further
validation of our results. Moreover, these data suggest that
many of the diverse proteins whose expression changed in re-
sponse to GA may be due to the reduced expression of Hsp90
clients and interactors other than, or in addition to, NPM-ALK.
For example, STIP1 has been shown to mediate the association
of the Hsp70-client protein complex with Hsp90 [39]. More-
over, the reduced expression of STIP1 may be indicative of
incapacitated Hsp90, and could serve as a surrogate marker of
disease states in which Hsp90 is overexpressed.
GA inhibits signal transduction by inducing ubiquitina-
tion and proteasomal degradation of proteins chaperoned by
Hsp90 [16, 20, 43]. Proteins associated with ubiquitin-medi-
ated proteasomal degradation machinery were differentially
expressed (overexpressed: PDC, CBLC, PSMD9, USP9X, and
PSMD7; underexpressed: PSMD2, CAPN5, and VCIP135).
Interestingly, two of the overexpressed proteins (PSMD9 and
PSMD7) are non-ATPase members of the 26S proteasome.
PDC functions in preventing proteins from being degraded
and associates with a subunit of the 26S proteasome/19S
regulatory complex [44, 45] suggesting that Hsp90 may reg-
ulate the expression of components of the proteasome.
In summary, our studies illustrate the diverse proteins
whose expression is changed due to GA inhibition of Hsp90.
Importantly, we identified proteins of both known and pre-
viously unreported signaling pathways downregulated in re-
sponse to GA-treatment. We also identified downregulated
Hsp90 client proteins and direct interactors as well as upreg-
ulation of proteins involved in the 26S proteasome. Our
studies illustrate the utility of a proteomics-based approach
in the identification and relative quantification of proteins
and signaling pathways involved in cancer pathogenesis and
the potential for exploitation of new knowledge thereby
obtained in approaches to the specifically targeting deranged
signaling pathways.
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